Management of Skin Toxicities from MKIs
Management of Skin Toxicities from MKIs
Dr Guillem Argilés, Paz Fernández Ortega, Prof. Siegfried Segaert
GI CONNECT has identified the Management of Skin Toxicities from Multikinase Inhibitor Therapies (MKIs) on the ESMO OncologyPRO portal as a practical guide on how to prevent and treat skin toxicities from MKIsDr Guillem Argilés
Medical Oncologist
Vall d'Hebron University Hospital
Spain
Dr Guillem Argilés obtained his medical degree at the Vall d’Hebron University Hospital in Barcelona, Spain. He later obtained his M.D., supervised by José Baselga M.D., in 2006 at the same institute. In 2010, he joined the Gastrointestinal Malignancies Division led by Josep Tabernero M.D., Ph.D. Dr Argilés currently works in the Gastrointestinal Malignancies and Developmental Therapeutics Divisions of the same institute, where his research is focused on chemorefractory colorectal cancer, personalized medicine, as well as the molecular biology of colorectal cancer.
Paz Fernández Ortega
Nursing Research Co-ordinator
Catalan Institute of Oncology
Spain
Paz Fernández Ortega has no relevant financial relationships to disclose.
Prof. Siegfried Segaert
Dermatologist
Leuven
Belgium
|
30 min
|
Sep 2019
This programme was made for you: your opinion matters
Share your feedback in just 4 clicks and help us to continue to create the content you need.
I agree that this educational programme:
Was valuable to me:
1/4
Has improved my knowledge of this topic:
2/4
Is likely to change my clinical practice:
3/4
Was balanced and unbiased:
4/4
This programme was made for you: your opinion matters
Share your feedback in just 4 clicks and help us to continue to create the content you need.
I agree that this educational programme:
Was valuable to me:
1/4
Has improved my knowledge of this topic:
2/4
Is likely to change my clinical practice:
3/4
Was balanced and unbiased:
4/4
Management of Skin Toxicities from Multi Kinase Inhibitors (MKIs)
Dr.Guillem Argilés (medical oncologist), Paz Fernández Ortega (clinical nurse specialist) and Prof. Siegfried Segaert (dermatologist) updated this helpful resource. With almost 100,000 visits, healthcare professionals continue to value the practical guidance available.
This important resource aims to;
1) Explore the side effects of inhibiting receptor tyrosine kinases (RTK)
2) Provide expert advice on the prophylaxis and treatment of skin toxicities
3) Provide recommendation on how to manage side effects while maintaining treatment with MKIs
Primarily this guidance exists for healthcare professionals and contains information, treatment algorithms and educational materials relating to the management of dermatological side effects in patients treated with MKIs.
However, there is also a helpful section for patients and caregivers on skin, mouth and hair changes that can sometimes occur with this particular type of treatment.
COR2ED have donated this content to ESMO to ensure that the practical guide reflects today's best clinical practice in managing skin toxicities from MKIs.
GI CONNECT is an initiative of COR2ED, supported by an Independent Educational Grant from Bayer.